Objectives: Evaluate the availability of buprenorphine/naloxone for inpatients with opioid use disorder in a state's acute care hospitals. Methods: An audit study of all acute care hospitals in New Mexico… Click to show full abstract
Objectives: Evaluate the availability of buprenorphine/naloxone for inpatients with opioid use disorder in a state's acute care hospitals. Methods: An audit study of all acute care hospitals in New Mexico was performed. Hospitals were surveyed on the availability of buprenorphine/naloxone on their inpatient formularies and their ability to obtain buprenorphine/naloxone within 1 day should a patient need it. Results: Of the surveyed hospitals, 45.5% did not have buprenorphine/naloxone on their inpatient formularies. Of the 26 counties in New Mexico with acute care hospitals, 10 did not have buprenorphine/naloxone available for inpatients. Three of these counties have drug overdose death rates equal to or higher than the state average. Conclusions: In 1 predominately rural state with an opioid overdose death rate higher than the national average, approximately half of acute care hospitals had buprenorphine/naloxone available to patients on their inpatient formulary. Efforts to increase buprenorphine/naloxone availability in hospitals are needed, particularly in rural areas where there may not be other locations to access treatment for opioid use disorder.
               
Click one of the above tabs to view related content.